Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases

Citation
B. Vergier et al., Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases, BLOOD, 95(7), 2000, pp. 2212-2218
Citations number
28
Categorie Soggetti
Hematology,"Cardiovascular & Hematology Research
Journal title
BLOOD
ISSN journal
00064971 → ACNP
Volume
95
Issue
7
Year of publication
2000
Pages
2212 - 2218
Database
ISI
SICI code
0006-4971(20000401)95:7<2212:TOMFCA>2.0.ZU;2-X
Abstract
The course of mycosis fungoides (MF) is indolent except when transformation to a large T-cell lymphoma occurs. The diagnosis of transformed MF (T-MF) relies on the presence of more than 25% of large cells on biopsy of an MF l esion. We analyzed 45 patients with T-MF recorded by the French Study Group on Cutaneous Lymphomas to better determine clinicopathological features of MF transformation and to analyze their impact on prognosis. Median time fr om diagnosis of MF to transformation was 6.5 years, Extracutaneous progress ion was present in 20 patients. Mean survival from transformation to death was 22 months. In univariate analysis, only an extracutaneous progression w as associated with a worse prognosis (5-year actuarial survival: 7.8% versu s 32%), Neither sex, age, clinical and skin disease stage at transformation , transformation speed, nor percentage of large cells or CD30 expression (1 4 of 45) had a prognostic value. When performing multivariate analysis, age (at least 60 years), and extracutaneous spreading were found to be associa ted with a poor prognosis. There was no difference between survival curves of patients with T-MF and with pleomorphic large T-cell CD30- lymphomas, Th e main diagnostic pitfall was "histiocytic-rich" MF, requiring CD68 stainin g for the diagnosis of T-MF, Out of 45 patients, 6 presented an histologic transformation before clinical progression, suggesting that an early histop athological diagnosis may be performed by histological followup. The progno stic value of such early histopathological diagnosis must be confirmed by p rospective studies, (Blood, 2000;95:2212-2218) (C) 2000 by The American Soc iety of Hematology.